AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences Launches CRISPR Detect8.6.2023 15:07:00 EEST | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced today the launch of CRISPR Detect, enabling single cell pooled CRISPR screens at unprecedented scale. Bulk pooled CRISPR screening has been a valuable tool to understand gene function on a genome scale. Adding single cell resolution to pooled CRISPR screens pairs individual gene perturbations with rich whole transcriptome expression phenotypes. This approach has expanded the capabilities of pooled CRISPR screening to understand cell types of perturbed cells and quantify changes in gene expression, regulatory networks, signaling pathways, and other complex signatures. However, the applications and scale of these studies have been limited by the throughput and cost of droplet-based single cell RNA-seq technology. CRISPR Detect brings the scale of existing Parse Evercode technology to single cell CRISPR screening by enabling users to pair perturbations and transcriptional profiles
FIFA Announces AB InBev as Official Beer Sponsor of FIFA Women’s World Cup 2023™ and FIFA World Cup 2026™8.6.2023 14:00:00 EEST | Press release
AB InBev (Euronext: ABI) (MEXBOL: ANB) (JSE: ANH) (NYSE: BUD), the world’s leading brewer, has extended its nearly 40-year partnership with FIFA as the official beer sponsor of the FIFA Women’s World Cup 2023™ and the FIFA World Cup 2026™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005239/en/ (Graphic: Business Wire) The two tournaments will make history with notable firsts, providing AB InBev and its leading brands with new opportunities to brew excitement for fans all around the world. The FIFA Women’s World Cup™ will make its debut in the southern hemisphere in Australia and Aotearoa New Zealand next month, with 32 teams also taking part in the competition for the first time. The FIFA World Cup 2026™, meanwhile, will be the first to be hosted by three countries, with 48 participating teams and 104 matches in 16 cities across Canada, Mexico and the United States. “FIFA World Cup tournaments are the most popular s
The IKEA Foundation Pledges More Than €11 Million in Emergency Humanitarian Aid for Sudan8.6.2023 13:23:00 EEST | Press release
The IKEA Foundation has donated €5 million to Médecins Sans Frontières - Doctors Without Borders (MSF) to provide urgent medical care and supplies to people affected by the recent fighting in Sudan. It has also donated €6.7 million to Better Shelter to deploy 3,000 units to meet the immediate shelter needs of people displaced by the deadly conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005375/en/ Illustration of fighting in Khartoum, Sudan Copyright: MSF/Atsuhiko Ochiai Countries: Sudan Date taken / Date Recorded: 04 May, 2023 Caption / Description: Aerial view captures the fighting and violence that erupted in Khartoum, Sudan. (Photo: Business Wire) Intense fighting broke out in Khartoum, Sudan on 15 April and has since spread to other parts of the country. Local hospitals have been overwhelmed as people arrive with serious injuries caused by gunshots, explosions and airstrikes. The country’s health system,
Digital Water Saves Millions for Communities, According to Leading Utilities8.6.2023 13:00:00 EEST | Press release
Leading water utilities are increasingly embracing data analytics and digital technology to optimize their operations, save millions for communities and increase water networks’ resilience to climate change. Insights from 18 global water utility leaders and experts that are influential in early-stage digital adoption are featured in a new paper from water technology leader Xylem (NYSE: XYL) and Bluefield Research. These utility experts share perspectives on how “going digital” is helping them to solve big water challenges in their communities. Their shared expertise provides a blueprint to accelerate the modernization of 400,000 water, wastewater, and stormwater systems worldwide. Utilities that participated in the paper implemented digital technology to save billions of gallons of water, prevent millions of gallons of sewer overflow pollution, and save millions of dollars in energy costs. For example, in Cincinnati, Ohio, the Metropolitan Sewer District of Greater Cincinnati used data
LTIMindtree and SNP Partner To Launch “Fast Forward” For BLUEFIELD™ Implementation8.6.2023 12:45:00 EEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, in collaboration with SNP Schneider-Neureither & Partner SE (ISIN: DE0007203705), a world-leading provider of software solutions for digital transformation processes, automated data migrations and data management in the SAP environment, today announced the launch of “Fast Forward” for BLUEFIELD™ implementation, powered by SNP’s proprietary approach. The joint offering – “Fast Forward” – is a full lifecycle solution built to accelerate an enterprise’s migration to the SAP S/4HANA platform with minimal risk, while retaining the golden nugget of existing ERP. It combines LTIMindtree’s global S/4HANA capability and industry knowledge with SNP’s CrystalBridge® platform and Rapid Empty Shell Creation technology to transform existing SAP investments without having to fully redesign their legacy systems. As part of the partnership, LTIMindtree and SNP will also set up a joint innovation center t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom